AstraZeneca Plc (NASDAQ:AZN) released high-level results from the CALYPSO Phase 3 trial designed to evaluate the efficacy and ...

Evommune, Inc., a clinical stage biotechnology company discovering and developing new ways to treat immune-mediated inflammatory diseases, today announced the enrollment of the first patient in a ...

The following is a summary of “Lipid abnormality in diabetic kidney disease and potential treatment advancements,” published ...

India contributes nearly one-sixth to the global disease burden of 422 million. Though diabetes is caused by a complex ...

"Learn about the importance of kidney health and comprehensive screening during National Kidney Month. Discover how CarelonRx ...

BPDCN is an aggressive hematologic malignancy with a historically poor prognosisVisualDx is a clinical decision support system used by more than ...

In the Phase III CALYPSO trial, eneboparatide demonstrated statistical significance in achieving albumin-adjusted serum calcium normalization while eliminating the need for active vitamin D and oral ...

Now the same team, along with their colleagues, have found signs of dementia-like brain damage, kidney and liver dysfunction, ...

Can plastic cause brain damage in seabirds? Research shows plastic pollution is harming their liver, kidneys, and even memory ...

The following is a summary of “Construction of a machine learning-based interpretable prediction model for acute kidney ...

Switching to IMVT-1402 extends the head starts Immunovant has already ceded to its rivals. Argenx won FDA approval for ...

The Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc.